162 related articles for article (PubMed ID: 36449764)
41. Abnormalities of fuel metabolism in the polycystic ovary syndrome.
Wortsman J; Soler NG
Obstet Gynecol; 1982 Sep; 60(3):342-5. PubMed ID: 6214733
[TBL] [Abstract][Full Text] [Related]
42. Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.
Sam S; Scoccia B; Yalamanchi S; Mazzone T
Hum Reprod; 2015 Jun; 30(6):1358-64. PubMed ID: 25857311
[TBL] [Abstract][Full Text] [Related]
43. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A
Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999
[TBL] [Abstract][Full Text] [Related]
44. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
45. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Patel R; Shah G
Curr Med Res Opin; 2017 Sep; 33(9):1545-1557. PubMed ID: 28058854
[TBL] [Abstract][Full Text] [Related]
46. Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 white patients with polycystic ovary syndrome.
Glintborg D; Mumm H; Hougaard DM; Ravn P; Andersen M
Gynecol Endocrinol; 2012 Mar; 28(3):170-4. PubMed ID: 21770838
[TBL] [Abstract][Full Text] [Related]
47. Association between visceral adiposity index, hirsutism and cardiometabolic risk factors in women with polycystic ovarian syndrome: A cross-sectional study.
Fonseka S; Subhani B; Wijeyaratne CN; Gawarammana IB; Kalupahana NS; Ratnatunga N; Rosairo S; Vithane KP
Ceylon Med J; 2019 Sep; 64(3):111-117. PubMed ID: 32120461
[TBL] [Abstract][Full Text] [Related]
48. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.
Li L; Feng Q; Ye M; He Y; Yao A; Shi K
J Obstet Gynaecol; 2017 Nov; 37(8):1036-1047. PubMed ID: 28657375
[TBL] [Abstract][Full Text] [Related]
49. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
[TBL] [Abstract][Full Text] [Related]
50. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.
Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212
[TBL] [Abstract][Full Text] [Related]
51. Plasma thiols and androgen levels in polycystic ovary syndrome.
Vrbíková J; Tallová J; Biciková M; Dvoráková K; Hill M; Stárka L
Clin Chem Lab Med; 2003 Feb; 41(2):216-21. PubMed ID: 12667010
[TBL] [Abstract][Full Text] [Related]
52. Oncostatin M Is Related to Polycystic Ovary Syndrome-Case Control Study.
Camili FE; Akis M; Adali E; Hismiogullari AA; Taskin MI; Guney G; Afsar S
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38397957
[No Abstract] [Full Text] [Related]
53. Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome.
Fulghesu A; Magnini R; Portoghese E; Angioni S; Minerba L; Melis GB
J Adolesc Health; 2010 May; 46(5):474-81. PubMed ID: 20413084
[TBL] [Abstract][Full Text] [Related]
54. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
55. Correlation between serum thyroid stimulating hormone level and glycolipid metabolism in patients with polycystic ovary syndrome.
Chen Z; Jing S; Sun Y
Medicine (Baltimore); 2023 Dec; 102(52):e36791. PubMed ID: 38206696
[TBL] [Abstract][Full Text] [Related]
56. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
57. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
[TBL] [Abstract][Full Text] [Related]
58. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study.
Korhonen S; Hippeläinen M; Niskanen L; Vanhala M; Saarikoski S
Am J Obstet Gynecol; 2001 Feb; 184(3):289-96. PubMed ID: 11228476
[TBL] [Abstract][Full Text] [Related]
59. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
60. Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
Tiwari N; Pasrija S; Jain S
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():149-154. PubMed ID: 30690191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
